Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 23
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Statins: Could an old friend help the fight against COVID-19?

  • Rodrigues-Diez, Raul R.
  • Tejera-Muñoz, Antonio
  • Marquez-Exposito, Laura
  • Rayego-Mateos, Sandra
  • Santos Sanchez, Laura
  • Marchant Hernández, Vanessa Alejandra
  • Tejedor Santamaria, Lucía
  • Ramos, Adrián M.
  • Ortiz Arduán, Alberto
  • Egido de los Ríos, Jesús
  • Ruiz Ortega, Marta
This is the peer reviewed version of the following article: "Statins: Could an old friend help the fight against COVID-19?" . British Journal of Pharmacology (2020): 19 June, which has been published in final form at https://doi.org/10.1111/bph.15166. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions, he COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID-19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID-19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS-CoV-2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well-known anti-inflammatory properties of statins, by blocking several molecular mechanisms, including NF-κB and NLRP3 inflammasomes, could limit the "cytokine storm" in severe COVID-19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID-19 outcomes, This work and data discussed here were supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigación Renal (REDINREN): RD16/0009, to M.R-O, PI17/01495 to J.E, PI18/01133 to AMR, PI19/00815 to A.O); Comunidad de Madrid (“NOVELREN” B2017/BMD3751 to M.R-O, B2017/BMD-3686 CIFRA2-CM to A.O); Spanish Ministry of Economy and Competitiveness MINECO (DTS17/00203, DTS19/00093) to J,E; “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN2019-103294 to M.R-O and SR-M); ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and DTS18/00032 to A.O; The “Sara Borrell” postdoctoral training program of the ISCIII supported the salary of SR-M (CD19/00021), IMPROVE-PD project (“Identification and Management of Patients at Risk–Outcome and Vascular Events in Peritoneal Dialysis”) funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 812699 to M.R.O.
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions

  • Kopytina, Valeria
  • Marchant, Vanessa
  • Rodrigues-Diez, Raquel
  • Pascual Antón, Lucía
  • Toggweiler, Nora
  • Strahl, Lisa
  • Kane, Jamie
  • Tejera Muñoz, Antonio
  • Cortés, Marcelino
  • Sucunza-Sáenz, David
  • Vaquero, Juan José
  • Vervloet, Marc
  • Piecha, Dorothea
  • Eringa, Etto C.
  • Ruiz-Ortega, Marta
  • López-Cabrera, Manuel
  • González-Mateo, Guadalupe Tirma
Background and hypothesis End-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and increased cardiovascular pathology. These complications can be exacerbated by exposure to PD solutions (PDS) containing glucose. This highlights the clinical unmet need for novel osmotic agents to replace glucose. Here, we tested troxerutin, a Food and Drug Administration–approved drug, as a potential osmotic agent. Methods To evaluate troxerutin osmotic and non-toxic effects, in vitro and in vivo experiments were carried out using artificial membranes, mice and cultured human mesothelial cells (MCs). The local and systemic consequences of chronic peritoneal exposure to PDS associated to renal insufficiency were investigated in a preclinical model. 5/6 nephrectomized C57BL/6J mice were daily exposed to glucose- or troxerutin-PDS for 60 days, then evaluating tissue damage, proinflammatory markers and cardiac damage. Results In vitro and in vivo studies revealed that troxerutin exhibits similar osmotic and ultrafiltration capacities to glucose, but with colloidal properties. Moreover, only glucose, but not troxerutin, reduced MC viability, induced mesothelial-to-mesenchymal transition, and increased damage markers (such as interleukin-6 and vascular endothelial growth factor A). In the preclinical model, long-term treatment with glucose-PDS, but not troxerutin-PDS, significantly increased peritoneal membrane thickening, tissue proinflammatory markers (evaluated in peritoneum, kidney, heart and aorta) and cardiovascular damage (cardiac hypertrophy and fibrosis) in mice. These preclinical data clearly demonstrate the wide deleterious effects of chronic peritoneal exposure to glucose-containing PDS in mice with kidney insufficiency and that the replacement of glucose with troxerutin notably reduces these effects. Conclusion Troxerutin emerges as a more biocompatible alternative to glucose as an osmotic agent for PD therapy, exhibiting no adverse local or systemic side effects in preclinical studies. This research presents a novel approach to reduce cardiovascular complications of PD in end-stage kidney disease, This project has received funding through the grant IMPROVE-PD from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 812699 to M.L.-C., V.K., M.R.-O., V.M., M.V. and E.C.E. This work was also supported by other grants from the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICIN/FEDER) to M.L.-C. (PID2022-142796OB-I00/A) and J.J.V. (PID2023-146343NB-I00). This study has also been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI20/00140, PI23/00394, RICORS2040 RD21/0005/0002, RD21/0005/0005, RD21/0005/0018, RD24/0004/0008, RD24/0004/0021, and RD24/0004/0028, and cofunded by the European Union-NextGenerationEU, Mecanismo para la recuperación y la resiliencia (MRR) to M.R.-O., J.J.V., D.S, and M.L.-C. INNOREN “P2022/BMD-7221: Nuevas estrategias diagnósticas y terapéuticas en enfermedad renal crónica” to V.M., M.R.-O. and J.J.V. E.C.E. is supported by the Dutch Heart Foundation and ZonMW
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Molecular Mechanisms of Kidney Injury and Repair

  • Rayego Mateos, Sandra
  • Marquez Exposito, Laura
  • Rodrigues Díez, Raquel
  • Sanz, Ana B.
  • Guiteras, Roser
  • Doladé Masot, Nuria
  • Rubio Soto, Irene
  • Manonelles Montero, Anna
  • Codina, Sergi
  • Ortiz, Alberto
  • Cruzado, Josep M.
  • Ruiz-Ortega, Marta
  • Sola, Anna
Chronic kidney disease (CKD) will become the fifth global cause of death by 2040, thus emphasizing the need to better understand the molecular mechanisms of damage and regeneration in the kidney. CKD predisposes to acute kidney injury (AKI) which, in turn, promotes CKD progression. This implies that CKD or the AKI-to-CKD transition are associated with dysfunctional kidney repair mechanisms. Current therapeutic options slow CKD progression but fail to treat or accelerate recovery from AKI and are unable to promote kidney regeneration. Unraveling the cellular and molecular mechanisms involved in kidney injury and repair, including the failure of this process, may provide novel biomarkers and therapeutic tools. We now review the contribution of different molecular and cellular events to the AKI-to-CKD transition, focusing on the role of macrophages in kidney injury, the different forms of regulated cell death and necroinflammation, cellular senescence and the senescence-associated secretory phenotype (SAPS), polyploidization, and podocyte injury and activation of parietal epithelial cells. Next, we discuss key contributors to repair of kidney injury and opportunities for their therapeutic manipulation, with a focus on resident renal progenitor cells, stem cells and their reparative secretome, certain macrophage subphenotypes within the M2 phenotype and senescent cell clearance., Instituto de Salud Carlos III (ISCIII) FEDER funds via the RICORS program: RICORS2040 (RD21/0005), FIS/ISCIII/FEDER (PI17/01411, PI17/00119, PI18/00910, PI18/01366, PI19/00588, PI19/00815, DTS18/00032, PI20/00140), ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009), Sociedad Española de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM and NOVELREN-CM: (B2017/BMD-3751 to M.R.-O). “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN2019-103294 to M.R.-O and S.R.-M); Juan de la Cierva incorporacion grant: IJC2018-035187-I to S.R-M, Innovation pro-gramme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMProve-PD ID: 812699) to M.R.-O
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment"

  • Ruiz-Ortega, Marta
  • Rodrigues-Diez, Raul
  • Lavoz, Carolina
  • Rayego Mateos, Sandra
Diabetic nephropathy (DN) is the main cause of end-stage renal disease. DN is a complex disease mediated by genetic and environmental factors, and many cellular and molecular mechanisms are involved in renal damage in diabetes. There are no biomarkers that reflect the severity of the underlying renal histopathological changes and can effectively predict the progression of renal damage and stratify the risk of DN among individuals with diabetes mellitus. Current therapeutic strategies are based on the strict control of glucose and blood pressure levels and, although there are new anti-diabetic drugs, these treatments only retard renal damage progression, being necessary novel therapies. In this Special Issue, there are several comprehensive reviews and interesting original papers covering all these topics, which would be of interest to the growing number of readers of the Journal of Clinical Medicine., Editors are funding by Grants from the Instituto de Salud Carlos III(ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigacion Renal (REDINREN): RD16/0009, to M.R-O), Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R-O); the Jose Castillejo grant (CAS19/00133 to R.R.R-D); the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supported the salary of SR-M (FJCI-2016-29050); Sociedad Espanola de Nefrologia (S.E.N. to M.R-O). Grants PAI 82140017 to C.L. of Chile; IMPROVE-PD project ("Identification and Management of Patients atRisk-Outcome and Vascular Events in Peritoneal Dialysis") funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 812699 to M.R.O.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

IL-17A as a potential therapeutic target for patients on peritoneal dialysis

  • Marchant, Vanessa
  • Tejera Muñoz, Antonio
  • Marquez Exposito, Laura
  • Rayego Mateos, Sandra
  • Rodrigues-Diez, Raul
  • Tejedor, Lucia
  • Santos Sanchez, Laura
  • Egido, Jesús
  • Valdivielso Revilla, José Manuel
  • Fraser, Donald J.
  • López Cabrera, Manuel
  • Selgas, Rafael
  • Ruiz-Ortega, Marta
Chronic kidney disease (CKD) is a health problem reaching epidemic proportions. There is no cure for CKD, and patients may progress to end-stage renal disease (ESRD). Peritoneal dialysis (PD) is a current replacement therapy option for ESRD patients until renal transplantation can be achieved. One important problem in long-term PD patients is peritoneal membrane failure. The mechanisms involved in peritoneal damage include activation of the inflammatory and immune responses, associated with submesothelial immune infiltrates, angiogenesis, loss of the mesothelial layer due to cell death and mesothelial to mesenchymal transition, and collagen accumulation in the submesothelial compact zone. These processes lead to fibrosis and loss of peritoneal membrane function. Peritoneal inflammation and membrane failure are strongly associated with additional problems in PD patients, mainly with a very high risk of cardiovascular disease. Among the inflammatory mediators involved in peritoneal damage, cytokine IL-17A has recently been proposed as a potential therapeutic target for chronic inflammatory diseases, including CKD. Although IL-17A is the hallmark cytokine of Th17 immune cells, many other cells can also produce or secrete IL-17A. In the peritoneum of PD patients, IL-17A-secreting cells comprise Th17 cells, gamma delta T cells, mast cells, and neutrophils. Experimental studies demonstrated that IL-17A blockade ameliorated peritoneal damage caused by exposure to PD fluids. This article provides a comprehensive review of recent advances on the role of IL-17A in peritoneal membrane injury during PD and other PD-associated complications., This research was funded by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 to M.R.-O.; PI17/01495, DTS17/00203, and DTS19/00093 to J.E.; PI16/02057 and PI19/00815 to A.O.; PI 15/00120 to R.S; PI18/0610 to J.M.V.; and Red de Investigacion Renal (REDINREN): RD16/0009 to M.R.-O., A.O., R.S., and J.M.V.); by Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R.-O. and B2017/BMD-3686 CIFRA2-CM to A.O.); by the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supporting the salary of S.R.-M. (FJCI-2016-29050); by "Convocatoria Dinamizacion Europa Investigacion 2019" MINECO (EIN2019-103294 to M.R.-O. and S.R.-M.); by Sociedad Espanola de Nefrologia (S.E.N. to M.R.-O.); by ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and DTS18/00032 toA.O; by IMPROVE-PD project ("Identification and Management of Patients at Risk-Outcome and Vascular Events in Peritoneal Dialysis") with funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 812699 to M.R.O., M.L.-C., and D.F.; and by the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICINN/FEDER) (PID2019-110132RB-I00) to M.L.-C.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Interleukin-17A: Potential mediator and therapeutic target in hypertension, Interleuquina-17A: potential mediador y diana terapéutica en la hipertensión

  • Rodrigues-Diez, Raul
  • Tejera Muñoz, Antonio
  • Orejudo, Macarena
  • Marquez Exposito, Laura
  • Santos Sanchez, Laura
  • Rayego Mateos, Sandra
  • Cantero-Navarro, Elena
  • Tejedor, Lucia
  • Marchant, Vanessa
  • Ortiz, Alberto
  • Egido, Jesús
  • Mezzano, Sergio
  • Selgas, Rafael
  • Navarro González, Juan F.
  • Valdivielso Revilla, José Manuel
  • Lavoz, Carolina
  • Ruiz-Ortega, Marta
Interleukin-17A (IL-17A) is a proinflammatory cytokine produced by cells of the immunesystem, predominantly Th17 and lymphocytes. In this paper, we review the role of IL-17A in the pathogenesis of hypertension and in target organ damage. Preclinical studiesin mice have shown that systemic adminstration of IL-17A increases blood pressure, prob-ably by acting on multiple levels. Furthermore, IL-17A plasma concentrations are alreadyelevated in patients with mild or moderate hypertension. Many studies in hypertensive mice models have detected IL-17A-producing cells in target organs such as the heart, vesselsand kidneys. Patients with hypertensive nephrosclerosis show kidney infiltration by Th17lymphocytes and lymphocytes that express IL-17A. In addition, in experimental models ofhypertension, the blockade of IL-17A by genetic strategies or using neutralizing antibodies,disminished blood pressure, probablyby acting on the small mesenteric arteries as well as inthe regulation of tubule sodium transport. Moreover, IL-17A inhibition reduces end-organsdamage. As a whole, the data presented in this review suggest that IL-17A participates in theregulation of blood pressure and in the genesis and maintenance of arterial hypertension,and may constitute a therapeutic target of hypertension-related pathologies in the future., La interleuquina 17A (IL-17A) es una citoquina proinflamatoria producida por células del sis-tema inmune, sobre todo por los linfocitos Th17 y los linfocitos . En este trabajo, revisamosel papel de IL-17A en la patogenia de la hipertensión y de la lesión en órganos diana. Estu-dios en ratones han demostrado que la IL-17A aumenta la presión arterial, probablementepor acciones a varios niveles. Además, las concentraciones plasmáticas de IL-17A están yaaumentadas en pacientes con hipertensión arterial ligera o moderada. Estudios preclíni-cos sobre hipertensión arterial han detectado células productoras de IL-17A en órganosdiana, como corazón, vasos y ri ̃nón. En pacientes con nefroesclerosis hipertensiva existeinfiltración del ri ̃nón por linfocitos Th17 y linfocitos que expresan IL-17A. Además, enmodelos experimentales de hipertensión el bloqueo de IL-17A, mediante estrategias génicas,o utilizando anticuerpos neutralizantes, disminuye la presión arterial por acciones sobre lapared vascular y el transporte tubular de sodio y disminuye la lesión en órganos diana. Enconjunto, los datos presentados en esta revisión sugieren que la IL-17A participa en la reg-ulación de la presión arterial y en la génesis y mantenimiento de la hipertensión arterial,pudiendo constituir una diana terapéutica en el futuro., This work has been funded by the Spanish Society of Nephrology and by grants from the Carlos III Health Institute (ISCIII) and FEDER European Union Funds (PI17/00119 and PI20/00140 and Renal Research Network (REDINREN): RD16/0009, to MR-O, RS, PI17/01495 to JE), Community of Madrid («NOVELREN» B2017/BMD3751 to MR-O); the José Castillejo grant (CAS19/00133 to RRR-D); «Juan de la Cierva Incorporacion» of the Ministry of Economy, Industry and Competitiveness (MINECO) for SR-M (IJC2018-035187-I); “Call for Dynamization Europe Research 2019” MINECO (EIN2019-103294 to MR-O and SR-M); IMPROVE-PD project («Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis») of Horizon 2020 MarieSkłodowska-Curie Grant Agreement No. 812699 to MRO, and Fondecyt Chile 1160465
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

B- and T-lymphocyte attenuator could be a new player in accelerated atherosclerosis associated with chronic kidney disease

  • Doladé Masot, Nuria
  • Rayego Mateos, Sandra
  • Garcia Carrasco, Alicia
  • Guerin, Maryse
  • Martín-Ventura, JL.
  • Ruiz-Ortega, Marta
  • Tharaux, Pierre-Louis
  • Valdivielso Revilla, José Manuel
Background: In chronic kidney disease (CKD), cardiovascular morbi-mortality is higher than in general population. Atherosclerotic cardiovascular disease is accelerated in CKD, but specific CKD-related risk factors for atherosclerosis are unknown. Methods: CKD patients from the NEFRONA study were used. We performed mRNA array from blood of patients free from atheroma plaque at baseline, with (n=10) and without (n=10) de novo atherosclerotic plaque development 2 years later. Selected mRNA candidates were validated in a bigger sample (n=148). Validated candidates were investigated in vivo in an experimental model of CKD-accelerated atherosclerosis, and in vitro in murine macrophages. Results: mRNA array analysis showed 92 up-regulated and 67 down-regulated mRNAs in samples from CKD patients with de novo plaque development. The functional analysis pointed to a paramount role of the immune response. The validation in a bigger sample confirmed that B- and T-lymphocyte co-inhibitory molecule (BTLA) down-regulation was associated with de novo plaque presence after 2 years. However, BTLA down-regulation was not found to be associated with atherosclerotic progression in patients with plaque already present at baseline. In a model of CKD-accelerated atherosclerosis, mRNA and protein expression levels of BTLA were significantly decreased in blood samples and atheroma plaques. Plaques from animals with CKD were bigger, had more infiltration of inflammatory cells, higher expression of IL6 and IL17 and less presence of collagen than plaques from control animals. Incubation of macrophages with rat uremic serum decreased BTLA expression. Conclusions: BTLA could be a potential biomarker or therapeutic target for atherosclerosis incidence in CKD patients., This research was funded by grants from the Instituto de Salud Carlos III and Fondos FEDER European Union PI20/00140, PI19/00815, DTS20/00083; PI15/00960, PI17/01089, PI18/610 and PI21/01099 (co-funded by the European Regional Development Fund “A way to achieve Europe” Red de Investigación Renal (REDinREN; RD12/0021)); Red de Investigación Renal REDINREN: RD16/0009/0003 to M.R-O and RICORS2040; RD21/0005/0002 funded by European Union. NextGenerationEU, Sociedad Española de Nefrología. “NOVELREN-CM: Enfermedad renal crónica: nuevas Estrategias para la prevención, Diagnóstico y tratamiento” (B2017/BMD-3751 to M.R-O). Juan de la Cierva incorporación grant: IJC2018-035187-I to S.R.-M.Innovation programme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMProve-PD ID: 812699) to M.R-O.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Could IL-17A be a novel therapeutic target in diabetic nephropathy?

  • Lavoz, Carolina
  • Rayego Mateos, Sandra
  • Orejudo, Macarena
  • Opazo Rios, Lucas
  • Marchant, Vanessa
  • Marquez Exposito, Laura
  • Tejera Muñoz, Antonio
  • Navarro González, Juan F.
  • Droguett, Alejandra
  • Ortiz, Alberto
  • Egido, Jesús
  • Mezzano, Sergio
  • Rodrigues-Diez, Raul
  • Ruiz-Ortega, Marta
Chronic kidney disease has become a major medical issue in recent years due to its high prevalence worldwide, its association with premature mortality, and its social and economic implications. A number of patients gradually progress to end-stage renal disease (ESRD), requiring then dialysis and kidney transplantation. Currently, approximately 40% of patients with diabetes develop kidney disease, making it the most prevalent cause of ESRD. Thus, more effective therapies for diabetic nephropathy are needed. In preclinical studies of diabetes, anti-inflammatory therapeutic strategies have been used to protect the kidneys. Recent evidence supports that immune cells play an active role in the pathogenesis of diabetic nephropathy. Th17 immune cells and their effector cytokine IL-17A have recently emerged as promising targets in several clinical conditions, including renal diseases. Here, we review current knowledge regarding the involvement of Th17/IL-17A in the genesis of diabetic renal injury, as well as the rationale behind targeting IL-17A as an additional therapy in patients with diabetic nephropathy., This work and data discussed here were supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigacion Renal (REDINREN): RD16/0009, to M.R.-O., PI17/01495, DTS17/00203 and DTS19/00093 to J.E., PI16/02057, PI19/00815 to A.O.); Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R.-O., B2017/BMD-3686 CIFRA2-CM to A.O.); the Jose Castillejo grant (CAS19/00133 to R.R.R.-D.); the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supported the salary of S.R.-M. (FJCI-2016-29050); "Convocatoria Dinamizacion Europa Investigacion 2019" MINECO (EIN2019-103294 to M.R.-O. and S.R.-M.); Sociedad Espanola de Nefrologia (S.E.N. to M.R.-O.). Grants Fondecyt 1160465 to S.M. and PAI 82140017 to C.L. of Chile; ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and DTS18/00032 to A.O.; IMPROVE-PD project ("Identification and Management of Patients at Risk-Outcome and Vascular Events in Peritoneal Dialysis") funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 812699 to M.R.O.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Molecular Mechanisms of Kidney Injury and Repair

  • Rayego Mateos, Sandra
  • Marquez Expósito, Laura
  • Rodrigues Diez, Raquel
  • Sanz, Ana B.
  • Guiteras, Roser
  • Doladé, Nuria
  • Rubio Soto, Irene
  • Manonelles, Anna
  • Codina, Sergi
  • Ortiz, Alberto
  • Cruzado, Josep Ma.
  • Ruiz Ortega, Marta
  • Sola, Anna
Chronic kidney disease (CKD) will become the fifth global cause of death by 2040, thus emphasizing the need to better understand the molecular mechanisms of damage and regeneration in the kidney. CKD predisposes to acute kidney injury (AKI) which, in turn, promotes CKD progression. This implies that CKD or the AKI-to-CKD transition are associated with dysfunctional kidney repair mechanisms. Current therapeutic options slow CKD progression but fail to treat or accelerate recovery from AKI and are unable to promote kidney regeneration. Unraveling the cellular and molecular mechanisms involved in kidney injury and repair, including the failure of this process, may provide novel biomarkers and therapeutic tools. We now review the contribution of different molecular and cellular events to the AKI-to-CKD transition, focusing on the role of macrophages in kidney injury, the different forms of regulated cell death and necroinflammation, cellular senescence and the senescence-associated secretory phenotype (SAPS), polyploidization, and podocyte injury and activation of parietal epithelial cells. Next, we discuss key contributors to repair of kidney injury and opportunities for their therapeutic manipulation, with a focus on resident renal progenitor cells, stem cells and their reparative secretome, certain macrophage subphenotypes within the M2 phenotype and senescent cell clearance.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Epigenetic Modulation of Gremlin-1/NOTCH Pathway in Experimental Crescentic Immune-Mediated Glomerulonephritis

  • Tejedor Santamaria, Lucia
  • Morgado Pascual, Jose Luis
  • Marquez Expósito, Laura
  • Suarez Alvarez, Beatriz
  • Rodrigues Diez, Raul R.
  • Tejera Muñoz, Antonio
  • Marchant, Vanessa
  • Mezzano, Sergio
  • López Larrea, Carlos
  • Sola, Anna
  • Fernandez Juarez, Gema Maria
  • Ortiz, Alberto
  • Rayego Mateos, Sandra
  • Ruiz Ortega, Marta
Crescentic glomerulonephritis is a devastating autoimmune disease that without early and properly treatment may rapidly progress to end-stage renal disease and death. Current immunosuppressive treatment provides limited efficacy and an important burden of adverse events. Epigenetic drugs are a source of novel therapeutic tools. Among them, bromodomain and extraterminal domain (BET) inhibitors (iBETs) block the interaction between bromodomains and acetylated proteins, including histones and transcription factors. iBETs have demonstrated protective effects on malignancy, inflammatory disorders and experimental kidney disease. Recently, Gremlin-1 was proposed as a urinary biomarker of disease progression in human anti-neutrophil cytoplasmic antibody (ANCA)-associated crescentic glomerulonephritis. We have now evaluated whether iBETs could regulate Gremlin-1 in experimental anti-glomerular basement membrane nephritis induced by nephrotoxic serum (NTS) in mice, a model resembling human crescentic glomerulonephritis. In NTS-injected mice, the iBET JQ1 inhibited renal Gremlin-1 overexpression and diminished glomerular damage, restoring podocyte numbers. Chromatin immunoprecipitation assay demonstrated BRD4 enrichment of the Grem-1 gene promoter in injured kidneys, consistent with Gremlin-1 epigenetic regulation. Moreover, JQ1 blocked BRD4 binding and inhibited Grem-1 gene transcription. The beneficial effect of iBETs was also mediated by modulation of NOTCH pathway. JQ1 inhibited the gene expression of the NOTCH effectors Hes-1 and Hey-1 in NTS-injured kidneys. Our results further support the role for epigenetic drugs, such as iBETs, in the treatment of rapidly progressive crescentic glomerulonephritis.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mesothelial-to-Mesenchymal Transition Contributes to the Generation of Carcinoma-Associated Fibroblasts in Locally Advanced Primary Colorectal Carcinomas

  • Gordillo, Carlos H.
  • Sandoval, Pilar
  • Muñoz-Hernández, Patricia
  • Pascual-Antón, Lucía
  • López-Cabrera, Manuel
  • Jiménez-Heffernan, José A.
© 2020 by the authors., During peritoneal metastasis, cancer cells spread from abdominal solid tumors, disseminate through the peritoneal fluid and attach to and invade through mesothelial cells (MCs) that line the peritoneum. Intestinal adenocarcinomas originating in the mucosa infiltrate the submucosa, muscle layer, and serosa in order to finally colonize the peritoneal cavity. However, the mechanism by which metastatic cells leave the primary tumor and reach the peritoneal cavity has not been previously described. Hence, we investigate whether MCs lining visceral peritoneum, through a mesothelial-to-mesenchymal transition (MMT), are a source of carcinoma-associated fibroblasts (CAFs), which could contribute to cancer progression toward the peritoneal cavity. CAFs detected in biopsies from patients with superficially invasive colorectal cancer differed from locally advanced tumors. An aberrant accumulation of myofibroblasts expressing mesothelial markers was found in the stroma of deeply infiltrative tumors located in the neighborhood of a frequently activated mesothelium. We suggest that MMT is a key event in the early stages of peritoneal dissemination., This work was supported by grants from SpanishMinistry of Economy, Industry and Competitiveness/Fondo Europeo de Desarrollo Regional (MINECO/FEDER) (SAF2016-80648-R) and Marie Sklodowska-Curie Innovative Training Networks-European Training Networks (812699) (both to Manuel López-Cabrera)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Alanyl-glutamine restores tight junction organization after disruption by a conventional peritoneal dialysis fluid

  • Bartosova, Maria
  • Herzog, Rebecca
  • Ridinger, David
  • Levai, Eszter
  • Jenei, Hanna
  • Zhang, Conghui
  • González-Mateo, Guadalupe
  • Marinovic, Iva
  • Hackert, Thilo
  • Bestvater, Felix
  • Hausmann, Michael
  • López Cabrera, Manuel
  • Kratochwill, Klaus
  • Zarogiannis, Sotirios G.
  • Schmitt, Claus Peter
Understanding and targeting the molecular basis of peritoneal solute and protein transport is essential to improve peritoneal dialysis (PD) efficacy and patient outcome. Supplementation of PD fluids (PDF) with alanyl-glutamine (AlaGln) increased small solute transport and reduced peritoneal protein loss in a recent clinical trial. Transepithelial resistance and 10 kDa and 70 kDa dextran transport were measured in primary human endothelial cells (HUVEC) exposed to conventional acidic, glucose degradation products (GDP) containing PDF (CPDF) and to low GDP containing PDF (LPDF) with and without AlaGln. Zonula occludens-1 (ZO-1) and claudin-5 were quantified by Western blot and immunofluorescence and in mice exposed to saline and CPDF for 7 weeks by digital imaging analyses. Spatial clustering of ZO-1 molecules was assessed by single molecule localization microscopy. AlaGln increased transepithelial resistance, and in CPDF exposed HUVEC decreased dextran transport rates and preserved claudin-5 and ZO-1 abundance. Endothelial clustering of membrane bound ZO-1 was higher in CPDF supplemented with AlaGln. In mice, arteriolar endothelial claudin-5 was reduced in CPDF, but restored with AlaGln, while mesothelial claudin-5 abundance was unchanged. AlaGln supplementation seals the peritoneal endothelial barrier, and when supplemented to conventional PD fluid increases claudin-5 and ZO-1 abundance and clustering of ZO-1 in the endothelial cell membrane., This work is part of the IMPROVE-PD project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement number 812699. M.B. is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—Projektnummer 419826430. R.H. was supported by a research fellowship of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA). E.L. was supported by the ÚNKP-18-2 New National Excellence Program of the Ministry of Human Capacities, Hungary. E.L. and H.J. were supported by Jellinek-Harry scholarship. S.G.Z. acknowledges the Alexander von Humboldt Stiftung/Foundation for an Experienced Researcher Fellowship (2019–2021) and the International Peritoneal Dialysis Society (ISPD) for an International Cooperation Research Grant (2019–2021). C.P.S. has obtained funding from European Nephrology and Dialysis Institute (ENDI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Increased miR-7641 levels in peritoneal hyalinizing vasculopathy in long-term peritoneal dialysis patients

  • Díaz, Raquel
  • Sandoval, Pilar
  • Rodrigues-Diez, Raul R.
  • Peso, Gloria del
  • Jiménez-Heffernan, José A.
  • Ramos-Ruiz, Ricardo
  • Llorens, Carlos
  • Laham, Gustavo
  • Alvarez-Quiroga, Mabel
  • López Cabrera, Manuel
  • Ruiz-Ortega, Marta
  • Bajo, María A.
  • Selgas, Rafael
Peritoneal hyalinizing vasculopathy (PHV) represents the cornerstone of long-term peritoneal dialysis (PD), and especially characterizes patients associated with encapsulating peritoneal sclerosis. However, the mechanisms of PHV development remain unknown. A cross sectional study was performed in 100 non-selected peritoneal biopsies of PD patients. Clinical data were collected and lesions were evaluated by immunohistochemistry. In selected biopsies a microRNA (miRNA)-sequencing analysis was performed. Only fifteen patients (15%) showed PHV at different degrees. PHV prevalence was significantly lower among patients using PD fluids containing low glucose degradation products (GDP) (5.9% vs. 24.5%), angiotensin converting enzyme inhibitors (ACEIs) (7.5% vs. 23.4%), statins (6.5% vs. 22.6%) or presenting residual renal function, suggesting the existence of several PHV protective factors. Peritoneal biopsies from PHV samples showed loss of endothelial markers and induction of mesenchymal proteins, associated with collagen IV accumulation and wide reduplication of the basement membrane. Moreover, co-expression of endothelial and mesenchymal markers, as well as TGF-β1/Smad3 signaling activation were found in PHV biopsies. These findings suggest that an endothelial-to-mesenchymal transition (EndMT) process was taking place. Additionally, significantly higher levels of miR-7641 were observed in severe PHV compared to non-PHV peritoneal biopsies. Peritoneal damage by GDPs induce miRNA deregulation and an EndMT process in submesothelial vessels, which could contribute to collagen IV accumulation and PHV., This research was funded by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI15/00120 to R.S, PI18/00882 to M.A.B, PI17/00119 to M.R.-O. and Red de Investigación Renal (REDINREN): RD16/0009, to R.S and M.R-O); “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN2019-103294 to M.R.-O.); IMPROVE-PD project (“Identification and Management of Patients at Risk–Outcome and Vascular Events in Peritoneal Dialysis”) funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 812699 to M.R.-O. and M.L-C. Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICINN/FEDER) (PID2019-110132RB-I00) to M.L.-C., Peer reviewed, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel aspects of the immune response involved in the peritoneal damage in chronic kidney disease patients under dialysis

  • Trionfetti, Flavia
  • Marchant, Vanessa
  • González-Mateo, Guadalupe
  • Kawka, Edyta
  • Márquez-Expósito, Laura
  • Ortiz, Alberto
  • López Cabrera, Manuel
  • Ruíz-Ortega, Marta
  • Strippoli, Raffaele
Chronic kidney disease (CKD) incidence is growing worldwide, with a significant percentage of CKD patients reaching end-stage renal disease (ESRD) and requiring kidney replacement therapies (KRT). Peritoneal dialysis (PD) is a convenient KRT presenting benefices as home therapy. In PD patients, the peritoneum is chronically exposed to PD fluids containing supraphysiologic concentrations of glucose or other osmotic agents, leading to the activation of cellular and molecular processes of damage, including inflammation and fibrosis. Importantly, peritonitis episodes enhance peritoneum inflammation status and accelerate peritoneal injury. Here, we review the role of immune cells in the damage of the peritoneal membrane (PM) by repeated exposure to PD fluids during KRT as well as by bacterial or viral infections. We also discuss the anti-inflammatory properties of current clinical treatments of CKD patients in KRT and their potential effect on preserving PM integrity. Finally, given the current importance of coronavirus disease 2019 (COVID-19) disease, we also analyze here the implications of this disease in CKD and KRT., This research was funded by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI20/00140, PI19/00815, and DTS20/00083). Red de Investigación Renal REDINREN: RD16/0009/0003 to M.R-O and RICORS2040; RD21/0005/0002 funded by European Union—NextGenerationEU, Sociedad Española de Nefrología. Innovation programme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMPROVE-PD ID: 812699) to M.R-O. E.K. was supported by the grant from the Narodowe Centrum Nauki (NCN, Polish National Science Centre; 2018/29/N/NZ3/02504). R.S. was supported by Ministry for Health of Italy (Ricerca Corrente). This work was also supported by a grant (PID 2019-110132RB-I00/AEI/10.13039/501100011033) from the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICINN/FEDER) to M.L.-C., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting carcinoma-associated mesothelial cells with antibody-drug conjugates in ovarian carcinomatosis

  • Pascual-Antón, Lucía
  • Sandoval, Pilar
  • González-Mateo, Guadalupe T.
  • Kopytina, Valeria
  • Tomero-Sanz, Henar
  • Arriero-País, Eva María
  • Jiménez-Heffernan, José Antonio
  • Fabre, Myriam
  • Egaña, Isabel
  • Ferrer, Cristina
  • Simón, Laureano
  • González-Cortijo, Lucía
  • Sainz de la Cuesta, Ricardo
  • López-Cabrera, Manuel
Ovarian carcinomatosis is characterized by the accumulation of carcinoma-associated mesothelial cells (CAMs) in the peritoneal stroma and mainly originates through a mesothelial-to-mesenchymal transition (MMT) process. MMT has been proposed as a therapeutic target for peritoneal metastasis. Most ovarian cancer (OC) patients present at diagnosis with peritoneal seeding, which makes tumor progression control difficult by MMT modulation. An alternative approach is to use antibody-drug conjugates (ADCs) targeted directly to attack CAMs. This strategy could represent the cornerstone of precision-based medicine for peritoneal carcinomatosis. Here, we performed complete transcriptome analyses of ascitic fluid-isolated CAMs in advanced OC patients with primary-, high-, and low-grade, serous subtypes and following neoadjuvant chemotherapy. Our findings suggest that both cancer biological aggressiveness and chemotherapy-induced tumor mass reduction reflect the MMT-associated changes that take place in the tumor surrounding microenvironment. Accordingly, MMT-related genes, including fibroblast activation protein (FAP), mannose receptor C type 2 (MRC2), interleukin-11 receptor alpha (IL11RA), myristoylated alanine-rich C-kinase substrate (MARCKS), and sulfatase-1 (SULF1), were identified as specific actionable targets in CAMs of OC patients, which is a crucial step in the de novo design of ADCs. These cell surface target receptors were also validated in peritoneal CAMs of colorectal cancer peritoneal implants, indicating that ADC-based treatment could extend to other abdominal tumors that show peritoneal colonization. As proof of concept, a FAP-targeted ADC reduced tumor growth in an OC xenograft mouse model with peritoneal metastasis-associated fibroblasts. In summary, we propose MMT as a potential source of ADC-based therapeutic targets for peritoneal carcinomatosis., This work was supported by the following grants to MLC: Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICINN/FEDER) Grant PID2019-110132RB-I00/AEI/10.13039/501100011033 and Marie Sklodowska-Curie Innovative Training Networks-European Training Networks Grant 812699., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Could IL-17A be a novel therapeutic target in diabetic nephropathy?

  • Lavoz, Carolina
  • Rayego Mateos, Sandra
  • Orejudo, Macarena
  • Opazo Rios, Lucas
  • Marchant, Vanessa
  • Marquez Exposito, Laura
  • Tejera Muñoz, Antonio
  • Navarro González, Juan F.
  • Droguett, Alejandra
  • Ortiz, Alberto
  • Egido, Jesús
  • Mezzano, Sergio
  • Rodrigues-Diez, Raul
  • Ruiz-Ortega, Marta
Chronic kidney disease has become a major medical issue in recent years due to its high prevalence worldwide, its association with premature mortality, and its social and economic implications. A number of patients gradually progress to end-stage renal disease (ESRD), requiring then dialysis and kidney transplantation. Currently, approximately 40% of patients with diabetes develop kidney disease, making it the most prevalent cause of ESRD. Thus, more effective therapies for diabetic nephropathy are needed. In preclinical studies of diabetes, anti-inflammatory therapeutic strategies have been used to protect the kidneys. Recent evidence supports that immune cells play an active role in the pathogenesis of diabetic nephropathy. Th17 immune cells and their effector cytokine IL-17A have recently emerged as promising targets in several clinical conditions, including renal diseases. Here, we review current knowledge regarding the involvement of Th17/IL-17A in the genesis of diabetic renal injury, as well as the rationale behind targeting IL-17A as an additional therapy in patients with diabetic nephropathy., This work and data discussed here were supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigacion Renal (REDINREN): RD16/0009, to M.R.-O., PI17/01495, DTS17/00203 and DTS19/00093 to J.E., PI16/02057, PI19/00815 to A.O.); Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R.-O., B2017/BMD-3686 CIFRA2-CM to A.O.); the Jose Castillejo grant (CAS19/00133 to R.R.R.-D.); the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supported the salary of S.R.-M. (FJCI-2016-29050); "Convocatoria Dinamizacion Europa Investigacion 2019" MINECO (EIN2019-103294 to M.R.-O. and S.R.-M.); Sociedad Espanola de Nefrologia (S.E.N. to M.R.-O.). Grants Fondecyt 1160465 to S.M. and PAI 82140017 to C.L. of Chile; ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and DTS18/00032 to A.O.; IMPROVE-PD project ("Identification and Management of Patients at Risk-Outcome and Vascular Events in Peritoneal Dialysis") funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 812699 to M.R.O.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Interleukin-17A: Potential mediator and therapeutic target in hypertension, Interleuquina-17A: potential mediador y diana terapéutica en la hipertensión

  • Rodrigues-Diez, Raul
  • Tejera Muñoz, Antonio
  • Orejudo, Macarena
  • Marquez Exposito, Laura
  • Santos Sanchez, Laura
  • Rayego Mateos, Sandra
  • Cantero-Navarro, Elena
  • Tejedor, Lucia
  • Marchant, Vanessa
  • Ortiz, Alberto
  • Egido, Jesús
  • Mezzano, Sergio
  • Selgas, Rafael
  • Navarro González, Juan F.
  • Valdivielso Revilla, José Manuel
  • Lavoz, Carolina
  • Ruiz-Ortega, Marta
Interleukin-17A (IL-17A) is a proinflammatory cytokine produced by cells of the immunesystem, predominantly Th17 and lymphocytes. In this paper, we review the role of IL-17A in the pathogenesis of hypertension and in target organ damage. Preclinical studiesin mice have shown that systemic adminstration of IL-17A increases blood pressure, prob-ably by acting on multiple levels. Furthermore, IL-17A plasma concentrations are alreadyelevated in patients with mild or moderate hypertension. Many studies in hypertensive mice models have detected IL-17A-producing cells in target organs such as the heart, vesselsand kidneys. Patients with hypertensive nephrosclerosis show kidney infiltration by Th17lymphocytes and lymphocytes that express IL-17A. In addition, in experimental models ofhypertension, the blockade of IL-17A by genetic strategies or using neutralizing antibodies,disminished blood pressure, probablyby acting on the small mesenteric arteries as well as inthe regulation of tubule sodium transport. Moreover, IL-17A inhibition reduces end-organsdamage. As a whole, the data presented in this review suggest that IL-17A participates in theregulation of blood pressure and in the genesis and maintenance of arterial hypertension,and may constitute a therapeutic target of hypertension-related pathologies in the future., La interleuquina 17A (IL-17A) es una citoquina proinflamatoria producida por células del sis-tema inmune, sobre todo por los linfocitos Th17 y los linfocitos . En este trabajo, revisamosel papel de IL-17A en la patogenia de la hipertensión y de la lesión en órganos diana. Estu-dios en ratones han demostrado que la IL-17A aumenta la presión arterial, probablementepor acciones a varios niveles. Además, las concentraciones plasmáticas de IL-17A están yaaumentadas en pacientes con hipertensión arterial ligera o moderada. Estudios preclíni-cos sobre hipertensión arterial han detectado células productoras de IL-17A en órganosdiana, como corazón, vasos y ri ̃nón. En pacientes con nefroesclerosis hipertensiva existeinfiltración del ri ̃nón por linfocitos Th17 y linfocitos que expresan IL-17A. Además, enmodelos experimentales de hipertensión el bloqueo de IL-17A, mediante estrategias génicas,o utilizando anticuerpos neutralizantes, disminuye la presión arterial por acciones sobre lapared vascular y el transporte tubular de sodio y disminuye la lesión en órganos diana. Enconjunto, los datos presentados en esta revisión sugieren que la IL-17A participa en la reg-ulación de la presión arterial y en la génesis y mantenimiento de la hipertensión arterial,pudiendo constituir una diana terapéutica en el futuro., This work has been funded by the Spanish Society of Nephrology and by grants from the Carlos III Health Institute (ISCIII) and FEDER European Union Funds (PI17/00119 and PI20/00140 and Renal Research Network (REDINREN): RD16/0009, to MR-O, RS, PI17/01495 to JE), Community of Madrid («NOVELREN» B2017/BMD3751 to MR-O); the José Castillejo grant (CAS19/00133 to RRR-D); «Juan de la Cierva Incorporacion» of the Ministry of Economy, Industry and Competitiveness (MINECO) for SR-M (IJC2018-035187-I); “Call for Dynamization Europe Research 2019” MINECO (EIN2019-103294 to MR-O and SR-M); IMPROVE-PD project («Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis») of Horizon 2020 MarieSkłodowska-Curie Grant Agreement No. 812699 to MRO, and Fondecyt Chile 1160465
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

IL-17A as a potential therapeutic target for patients on peritoneal dialysis

  • Marchant, Vanessa
  • Tejera Muñoz, Antonio
  • Marquez Exposito, Laura
  • Rayego Mateos, Sandra
  • Rodrigues-Diez, Raul
  • Tejedor, Lucia
  • Santos Sanchez, Laura
  • Egido, Jesús
  • Valdivielso Revilla, José Manuel
  • Fraser, Donald J.
  • López Cabrera, Manuel
  • Selgas, Rafael
  • Ruiz-Ortega, Marta
Chronic kidney disease (CKD) is a health problem reaching epidemic proportions. There is no cure for CKD, and patients may progress to end-stage renal disease (ESRD). Peritoneal dialysis (PD) is a current replacement therapy option for ESRD patients until renal transplantation can be achieved. One important problem in long-term PD patients is peritoneal membrane failure. The mechanisms involved in peritoneal damage include activation of the inflammatory and immune responses, associated with submesothelial immune infiltrates, angiogenesis, loss of the mesothelial layer due to cell death and mesothelial to mesenchymal transition, and collagen accumulation in the submesothelial compact zone. These processes lead to fibrosis and loss of peritoneal membrane function. Peritoneal inflammation and membrane failure are strongly associated with additional problems in PD patients, mainly with a very high risk of cardiovascular disease. Among the inflammatory mediators involved in peritoneal damage, cytokine IL-17A has recently been proposed as a potential therapeutic target for chronic inflammatory diseases, including CKD. Although IL-17A is the hallmark cytokine of Th17 immune cells, many other cells can also produce or secrete IL-17A. In the peritoneum of PD patients, IL-17A-secreting cells comprise Th17 cells, gamma delta T cells, mast cells, and neutrophils. Experimental studies demonstrated that IL-17A blockade ameliorated peritoneal damage caused by exposure to PD fluids. This article provides a comprehensive review of recent advances on the role of IL-17A in peritoneal membrane injury during PD and other PD-associated complications., This research was funded by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 to M.R.-O.; PI17/01495, DTS17/00203, and DTS19/00093 to J.E.; PI16/02057 and PI19/00815 to A.O.; PI 15/00120 to R.S; PI18/0610 to J.M.V.; and Red de Investigacion Renal (REDINREN): RD16/0009 to M.R.-O., A.O., R.S., and J.M.V.); by Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R.-O. and B2017/BMD-3686 CIFRA2-CM to A.O.); by the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supporting the salary of S.R.-M. (FJCI-2016-29050); by "Convocatoria Dinamizacion Europa Investigacion 2019" MINECO (EIN2019-103294 to M.R.-O. and S.R.-M.); by Sociedad Espanola de Nefrologia (S.E.N. to M.R.-O.); by ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and DTS18/00032 toA.O; by IMPROVE-PD project ("Identification and Management of Patients at Risk-Outcome and Vascular Events in Peritoneal Dialysis") with funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 812699 to M.R.O., M.L.-C., and D.F.; and by the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICINN/FEDER) (PID2019-110132RB-I00) to M.L.-C.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Molecular Mechanisms of Kidney Injury and Repair

  • Rayego Mateos, Sandra
  • Marquez Exposito, Laura
  • Rodrigues Díez, Raquel
  • Sanz, Ana B.
  • Guiteras, Roser
  • Doladé Masot, Nuria
  • Rubio Soto, Irene
  • Manonelles Montero, Anna
  • Codina, Sergi
  • Ortiz, Alberto
  • Cruzado, Josep M.
  • Ruiz-Ortega, Marta
  • Sola, Anna
Chronic kidney disease (CKD) will become the fifth global cause of death by 2040, thus emphasizing the need to better understand the molecular mechanisms of damage and regeneration in the kidney. CKD predisposes to acute kidney injury (AKI) which, in turn, promotes CKD progression. This implies that CKD or the AKI-to-CKD transition are associated with dysfunctional kidney repair mechanisms. Current therapeutic options slow CKD progression but fail to treat or accelerate recovery from AKI and are unable to promote kidney regeneration. Unraveling the cellular and molecular mechanisms involved in kidney injury and repair, including the failure of this process, may provide novel biomarkers and therapeutic tools. We now review the contribution of different molecular and cellular events to the AKI-to-CKD transition, focusing on the role of macrophages in kidney injury, the different forms of regulated cell death and necroinflammation, cellular senescence and the senescence-associated secretory phenotype (SAPS), polyploidization, and podocyte injury and activation of parietal epithelial cells. Next, we discuss key contributors to repair of kidney injury and opportunities for their therapeutic manipulation, with a focus on resident renal progenitor cells, stem cells and their reparative secretome, certain macrophage subphenotypes within the M2 phenotype and senescent cell clearance., Instituto de Salud Carlos III (ISCIII) FEDER funds via the RICORS program: RICORS2040 (RD21/0005), FIS/ISCIII/FEDER (PI17/01411, PI17/00119, PI18/00910, PI18/01366, PI19/00588, PI19/00815, DTS18/00032, PI20/00140), ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009), Sociedad Española de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM and NOVELREN-CM: (B2017/BMD-3751 to M.R.-O). “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN2019-103294 to M.R.-O and S.R.-M); Juan de la Cierva incorporacion grant: IJC2018-035187-I to S.R-M, Innovation pro-gramme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMProve-PD ID: 812699) to M.R.-O
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Molecular Mechanisms of Kidney Injury and Repair

  • Rayego Mateos, Sandra
  • Marquez Expósito, Laura
  • Rodrigues Diez, Raquel
  • Sanz, Ana B.
  • Guiteras, Roser
  • Doladé, Nuria
  • Rubio Soto, Irene
  • Manonelles, Anna
  • Codina, Sergi
  • Ortiz, Alberto
  • Cruzado, Josep Ma.
  • Ruiz Ortega, Marta
  • Sola, Anna
Chronic kidney disease (CKD) will become the fifth global cause of death by 2040, thus emphasizing the need to better understand the molecular mechanisms of damage and regeneration in the kidney. CKD predisposes to acute kidney injury (AKI) which, in turn, promotes CKD progression. This implies that CKD or the AKI-to-CKD transition are associated with dysfunctional kidney repair mechanisms. Current therapeutic options slow CKD progression but fail to treat or accelerate recovery from AKI and are unable to promote kidney regeneration. Unraveling the cellular and molecular mechanisms involved in kidney injury and repair, including the failure of this process, may provide novel biomarkers and therapeutic tools. We now review the contribution of different molecular and cellular events to the AKI-to-CKD transition, focusing on the role of macrophages in kidney injury, the different forms of regulated cell death and necroinflammation, cellular senescence and the senescence-associated secretory phenotype (SAPS), polyploidization, and podocyte injury and activation of parietal epithelial cells. Next, we discuss key contributors to repair of kidney injury and opportunities for their therapeutic manipulation, with a focus on resident renal progenitor cells, stem cells and their reparative secretome, certain macrophage subphenotypes within the M2 phenotype and senescent cell clearance.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

B- and T-lymphocyte attenuator could be a new player in accelerated atherosclerosis associated with chronic kidney disease

  • Doladé Masot, Nuria
  • Rayego Mateos, Sandra
  • Garcia Carrasco, Alicia
  • Guerin, Maryse
  • Martín-Ventura, JL.
  • Ruiz-Ortega, Marta
  • Tharaux, Pierre-Louis
  • Valdivielso Revilla, José Manuel
Background: In chronic kidney disease (CKD), cardiovascular morbi-mortality is higher than in general population. Atherosclerotic cardiovascular disease is accelerated in CKD, but specific CKD-related risk factors for atherosclerosis are unknown. Methods: CKD patients from the NEFRONA study were used. We performed mRNA array from blood of patients free from atheroma plaque at baseline, with (n=10) and without (n=10) de novo atherosclerotic plaque development 2 years later. Selected mRNA candidates were validated in a bigger sample (n=148). Validated candidates were investigated in vivo in an experimental model of CKD-accelerated atherosclerosis, and in vitro in murine macrophages. Results: mRNA array analysis showed 92 up-regulated and 67 down-regulated mRNAs in samples from CKD patients with de novo plaque development. The functional analysis pointed to a paramount role of the immune response. The validation in a bigger sample confirmed that B- and T-lymphocyte co-inhibitory molecule (BTLA) down-regulation was associated with de novo plaque presence after 2 years. However, BTLA down-regulation was not found to be associated with atherosclerotic progression in patients with plaque already present at baseline. In a model of CKD-accelerated atherosclerosis, mRNA and protein expression levels of BTLA were significantly decreased in blood samples and atheroma plaques. Plaques from animals with CKD were bigger, had more infiltration of inflammatory cells, higher expression of IL6 and IL17 and less presence of collagen than plaques from control animals. Incubation of macrophages with rat uremic serum decreased BTLA expression. Conclusions: BTLA could be a potential biomarker or therapeutic target for atherosclerosis incidence in CKD patients., This research was funded by grants from the Instituto de Salud Carlos III and Fondos FEDER European Union PI20/00140, PI19/00815, DTS20/00083; PI15/00960, PI17/01089, PI18/610 and PI21/01099 (co-funded by the European Regional Development Fund “A way to achieve Europe” Red de Investigación Renal (REDinREN; RD12/0021)); Red de Investigación Renal REDINREN: RD16/0009/0003 to M.R-O and RICORS2040; RD21/0005/0002 funded by European Union. NextGenerationEU, Sociedad Española de Nefrología. “NOVELREN-CM: Enfermedad renal crónica: nuevas Estrategias para la prevención, Diagnóstico y tratamiento” (B2017/BMD-3751 to M.R-O). Juan de la Cierva incorporación grant: IJC2018-035187-I to S.R.-M.Innovation programme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMProve-PD ID: 812699) to M.R-O.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment"

  • Ruiz-Ortega, Marta
  • Rodrigues-Diez, Raul
  • Lavoz, Carolina
  • Rayego Mateos, Sandra
Diabetic nephropathy (DN) is the main cause of end-stage renal disease. DN is a complex disease mediated by genetic and environmental factors, and many cellular and molecular mechanisms are involved in renal damage in diabetes. There are no biomarkers that reflect the severity of the underlying renal histopathological changes and can effectively predict the progression of renal damage and stratify the risk of DN among individuals with diabetes mellitus. Current therapeutic strategies are based on the strict control of glucose and blood pressure levels and, although there are new anti-diabetic drugs, these treatments only retard renal damage progression, being necessary novel therapies. In this Special Issue, there are several comprehensive reviews and interesting original papers covering all these topics, which would be of interest to the growing number of readers of the Journal of Clinical Medicine., Editors are funding by Grants from the Instituto de Salud Carlos III(ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigacion Renal (REDINREN): RD16/0009, to M.R-O), Comunidad de Madrid ("NOVELREN" B2017/BMD-3751 to M.R-O); the Jose Castillejo grant (CAS19/00133 to R.R.R-D); the "Juan de la Cierva Formacion" training program of the Ministerio de Economia, Industria y Competitividad (MINECO) supported the salary of SR-M (FJCI-2016-29050); Sociedad Espanola de Nefrologia (S.E.N. to M.R-O). Grants PAI 82140017 to C.L. of Chile; IMPROVE-PD project ("Identification and Management of Patients atRisk-Outcome and Vascular Events in Peritoneal Dialysis") funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 812699 to M.R.O.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenetic Modulation of Gremlin-1/NOTCH Pathway in Experimental Crescentic Immune-Mediated Glomerulonephritis

  • Tejedor Santamaria, Lucia
  • Morgado Pascual, Jose Luis
  • Marquez Expósito, Laura
  • Suarez Alvarez, Beatriz
  • Rodrigues Diez, Raul R.
  • Tejera Muñoz, Antonio
  • Marchant, Vanessa
  • Mezzano, Sergio
  • López Larrea, Carlos
  • Sola, Anna
  • Fernandez Juarez, Gema Maria
  • Ortiz, Alberto
  • Rayego Mateos, Sandra
  • Ruiz Ortega, Marta
Crescentic glomerulonephritis is a devastating autoimmune disease that without early and properly treatment may rapidly progress to end-stage renal disease and death. Current immunosuppressive treatment provides limited efficacy and an important burden of adverse events. Epigenetic drugs are a source of novel therapeutic tools. Among them, bromodomain and extraterminal domain (BET) inhibitors (iBETs) block the interaction between bromodomains and acetylated proteins, including histones and transcription factors. iBETs have demonstrated protective effects on malignancy, inflammatory disorders and experimental kidney disease. Recently, Gremlin-1 was proposed as a urinary biomarker of disease progression in human anti-neutrophil cytoplasmic antibody (ANCA)-associated crescentic glomerulonephritis. We have now evaluated whether iBETs could regulate Gremlin-1 in experimental anti-glomerular basement membrane nephritis induced by nephrotoxic serum (NTS) in mice, a model resembling human crescentic glomerulonephritis. In NTS-injected mice, the iBET JQ1 inhibited renal Gremlin-1 overexpression and diminished glomerular damage, restoring podocyte numbers. Chromatin immunoprecipitation assay demonstrated BRD4 enrichment of the Grem-1 gene promoter in injured kidneys, consistent with Gremlin-1 epigenetic regulation. Moreover, JQ1 blocked BRD4 binding and inhibited Grem-1 gene transcription. The beneficial effect of iBETs was also mediated by modulation of NOTCH pathway. JQ1 inhibited the gene expression of the NOTCH effectors Hes-1 and Hey-1 in NTS-injured kidneys. Our results further support the role for epigenetic drugs, such as iBETs, in the treatment of rapidly progressive crescentic glomerulonephritis.